El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Miniatura

Fitxers

medicina-59-01362.pdf (313.84 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2023-07-25

Llicència de publicació

cc by (c) Capdevila, O. et al., 2023
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/201929

Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3390/medicina59081362

Resum

Objectives: To analyze the characteristics and the predictive factors of the use of rituximab and belimumab in daily practice in patients from the inception cohort Registro Espanol de Lupus (RELES). Material and methods: The study included 518 patients. We considered patients treated with biologics who received at least one dose of rituximab or belimumab, and possible indications of those manifestations registered at the same time or in the previous 2 months of the start of the therapy. Results: In our cohort, 37 (7%) patients received at least one biological treatment. Rituximab was prescribed in 26 patients and belimumab in 11. Rituximab was mainly prescribed for hemolytic anemia or thrombocytopenia (11 patients, 42%), lupus nephritis and neuropsychiatric lupus (5 patients each, 19%). Belimumab was mostly used for arthritis (8 patients, 73%). In the univariate analysis, the predictive factors at diagnosis for the use of biologic therapy were younger age (p = 0.022), a higher SLEDAI (p = 0.001) and the presence of psychosis (p = 0.011), organic mental syndrome (SOCA) (p = 0.006), hemolytic anemia (p = 0.001), or thrombocytopenia (p = 0.01). In the multivariant model, only younger age, psychosis, and hemolytic anemia were independent predictors of the use of biologics. Conclusions: Rituximab is usually given to patients with hematological, neuropsychiatric and renal involvement and belimumab for arthritis. Psychosis, hemolytic anemia and age at the diagnosis of lupus were independent predictive factors of the use of biological agents. Their global effects are beneficial, with a significant reduction in SLE activity and a low rate of side effects.

Matèries

Lupus eritematós, Rituximab, Artritis, Productes biològics, Ús terapèutic

Matèries (anglès)

Lupus erythematosus, Rituximab, Arthritis, Biological products, Therapeutic use

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

CAPDEVILA, Olga, MITJAVILA VILLERÓ, Francesca, ESPINOSA GARRIGA, Gerard, CAMINAL MONTERO, L., MARÍN BALLVÈ, A., GONZÁLEZ LEÓN, R., CASTRO, A., CANORA, J., PINILLA LLORENTE, Blanca, FONSECA, E., RUIZ IRASTORZA, G., RELES, Autoimmune diseases study group (geas). Predictive Factors of the Use of Rituximab and Belimumab in Spanish Lupus Patients. _Medicina_. 2023. Vol. 59, núm. 8, pàgs. 1362. [consulta: 1 de gener de 2026]. ISSN: 1648-9144. [Disponible a: https://hdl.handle.net/2445/201929]

Exportar metadades

JSON - METS

Compartir registre